ClinicalTrials.gg
CompletedNCT07263698Updated May 26, 2026

Investigation of Clinical Efficacy of a New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems as Compared to a Control Mouthwash

A Phase 3 interventional study of cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash and sodium fluoride Mouthwash in Gingivitis and Plaque, Dental, sponsored by Colgate Palmolive. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Colgate Palmolive · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Gingivitis by Colgate Palmolive — 8 open to participants now, 9 under way, 5 of them phase 3. Gingivitis · Colgate Palmolive.

Enrollment
34th of 44
80 · median 94
Started
2025
with 5 others
Phase 3
25 of 44
4 open now
Registered
33rd of 44
by date

Among the 44 studies in Gingivitis by Colgate Palmolive, this one is the 34th largest by enrollment, is one of 6 that started in 2025, is one of 25 in phase 3, and was the 33rd registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

8 of the 44 studies in Gingivitis by Colgate Palmolive are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Gingivitis by Colgate Palmolive, or all of them as a file.
02

Study summary

Qualified subjects will be enrolled and randomized to either one of the two study groups described above based on their initial modified gingivitis and plaque scores. Subjects will be instructed to use the products according to the instructions provided. Subjects will return to the dental office for evaluation after two weeks, six weeks and three months of product use. All subjects will be followed for adverse events throughout the study

03

Conditions studied

  • Gingivitis
  • Plaque, Dental

Keywords

  • Quigley-Hein Plaque Index
  • Modified Gingival
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects, ages 18-70, inclusive.
  • Availability for the three-month duration of the clinical research study.
  • Good general health.
  • Initial modified gingivitis index of at least 1.5 as determined by the use of the Modified Gingival Index.
  • Initial plaque index of at least 1.5 as determined by the use of the Quigley-Hein Plaque Index.
  • Signed Form (Appendix C)

Exclusion criteria

Exclusion Criteria:

  • Presence of orthodontic bands.
  • Tumor(s) of the soft or hard tissues of the oral cavity.
  • Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).
  • Five or more carious lesions requiring immediate restorative treatment.
  • Antibiotic use any time during the one-month period prior to entry into the study.
  • Participation in any other clinical study or test panel within the one month prior to entry into the study.
  • Dental prophylaxis during the past two weeks prior to baseline examinations.
  • History of allergies to oral care/personal care consumer products or their ingredients.
  • On any prescription medicines that might interfere with the study outcome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Test 1 mouthwash

    After brushing in the morning and in the evening, 20 ml of mouthwash shall be used for each rinsing, 2 times daily (morning and evening) for 30 seconds each time. No further rinsing with water shall be occurred after each mouthwash rising. Each qualified subject will follow this specific application for 3 months

    Drug: cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash

  • Active comparator
    Test 2 mouthwash

    After brushing either in the morning or in the evening, 20 ml of the mouthwash shall be used for each rinsing, 2 times daily (morning and evening) for 30 seconds each time

    Drug: sodium fluoride Mouthwash

Interventions

06

What researchers measure

Primary outcomes

  1. Modified Gingival Index

    A Modified Gingivitis Index score from 0 to 4 will be assigned by the examiner to all tooth surfaces. In regards to the scale, lower number is a better outcome.

    Time frame: baseline, 2 week, 6 week & 3 month

  2. Saxton Bleeding Index

    Gingival bleeding is assessed 30 seconds after probing; a score of 0 represents an absence of bleeding. a score of 1 is given if bleeding is observed within 30 seconds after probing and a score of 2 is given if bleeding is observed immediately on probing

    Time frame: baseline, 2 week, 6 week & 3 month

  3. Modified Quigley-Hein Plaque Index

    Modified Quigley-Hein Plaque Index score of 0 to 5 will be assigned to all scoreable disclosed tooth surfaces. In regards to the scale, lower number is a better outcome.

    Time frame: baseline, 2 week, 6 week & 3 month

07

Study locations

1 site
  • Clinica Odontoiatrica Montesani
    Roma, Rome 00187, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Feb 2026, 2 months.

Of 23 industry-sponsored phase 3 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 2 months is below that.

Counting every sponsor, half of 35 studies reached it within 3 months; a quarter within 2 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartActual
Dec 1, 2025
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07263698
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 1, 2025
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
May 26, 2026

Study contacts

Luigi Montesani, DDS
principal investigator · University of Rome

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetylpyridinium · Zinc lactate · Sodium Fluoride

Start the discussion